Research
Cellular
SGLT2 inhibitors may slow the progression of chronic kidney disease in high-risk individuals with type 2 diabetes.
SGLT2 inhibitors should be considered for patients at risk of chronic kidney disease.
StrongSupportsmedium confidence
The SGLT2 inhibitor, empagliflozin, slowed down the progression of chronic kidney disease.
Why this rating
Based on the mention of the EMPA-REG OUTCOME trial.
Source
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Ban Liu et al. · Current Topics in Medicinal Chemistry · 2019
DOI 10.2174/1568026619666190828161409
reviewCited 41×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →